Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Alemtuzumab for the Treatment of Multiple Sclerosis
MRI as an outcome in multiple sclerosis clinical trials.
Masitinib mesylate application for conditional approval
Multiple Sclerosis: Vitamin D and calcium as environmental determinants of prevalence (A Viewpoint)
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis
"Undiagnosing" multiple sclerosis: The challenge of misdiagnosis in MS.
Multiple sclerosis, vitamin D, and HLA-DRB1*15.
Disability as an outcome in MS clinical trials.
Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa.
Balance impairment in people with multiple sclerosis: Preliminary evidence for the Balance Evaluation Systems Test.
Clinical profile of malay children with optic neuritis.
Vitamin D intake and incidence of multiple sclerosis.
Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.
Studies on the natural history of multiple sclerosis. 3. Epidemiologic analysis of the army experience in World War II.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
The complex role of estrogens in inflammation.
Is progressive multiple sclerosis a gray matter disease?
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Severe haematological complications during treatment with natalizumab.

Pages